Revista Urología Colombiana / Colombian Urology Journal, Inhaltsverzeichnis CC BY-NC-ND 4.0 · Revista Urología Colombiana / Colombian Urology Journal 2018; 27(03): 203-213DOI: 10.1055/s-0038-1676044 SCU Guidelines | Guias Clinicas SCU Sociedad Colombiana de Urología. Publicado por Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil Resumen de la Guía de Práctica Clínica de Disfunción Eréctil – Sociedad Colombiana de Urología Clinical Practice Guideline for Erectile Dysfunction – Colombian Society of Urology María del Pilar Ceballos 1 Urólogo, Medicina Sexual, Bogotá, Bogotá, Colombia , Juan Fernando Uribe Arcila 2 Urólogo, Medicina Sexual, PAR EXTERNO REVISOR DE GUIA, Sociedad Latinoamericana de Medicina Sexual – SLAMS, Sociedad de Medicina Sexual de Norte América – SMSNA, Vicepresidente de la SCU, Bogotá, Colombia › Institutsangaben Artikel empfehlen Abstract Volltext Referenzen Bibliografía 1 McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl. 04) S6-S11 2 Lue T, Basson R, Rosen R, Guiliano F, Khoury S. Sexual Medicine: Sexual Dysfunctions in men and Women. Paris: Health Prod; 2004 3 Morillo LE, Díaz J, Estevez E. , et al. Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: a population-based study (DENSA). Int J Impot Res 2002; 14 (Suppl. 02) S10-S18 4 Acuña Cañas A, Ceballos Domínguez MP, López Ramos H, Suárez PA. Investigación Original Síndrome metabólico y disfunción eréctil en la población colombiana Urol.colomb. Vol XX, No. 3: pp. 55–60, 2011 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Erectile Disorder DSM-5 302.72 (F52.21) Arlington, VA: American Psychiatric Publishing ; 2013 6 McCabe MP, Sharlip ID, Atalla E. , et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016; 13 (02) 135-143 7 Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151 (01) 54-61 8 Feldman HA, Johannes CB, Derby CA. , et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000; 30 (04) 328-338 9 Tengs TO, Osgood ND. The link between smoking and impotence: two decades of evidence. Prev Med 2001; 32 (06) 447-452 10 Hirshkowitz M, Karacan I, Howell JW, Arcasoy MO, Williams RL. Nocturnal penile tumescence in cigarette smokers with erectile dysfunction. Urology 1992; 39 (02) 101-107 11 Allen MS, Walter EE. Health-Related Lifestyle Factors and Sexual Dysfunction: A Meta-Analysis of Population-Based Research. J Sex Med 2018; 15 (4): 458-475 12 Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J Urol 2005; 174 (01) 244-248 13 Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens 2008; 26 (11) 2074-2084 14 Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep 2012; 14 (04) 285-292 15 Weinhardt LS, Carey MP. Prevalence of erectile disorder among men with diabetes mellitus: comprehensive review, methodological critique and suggestions for future research. J Sex Res 1996; 33: 205-214 16 Gazzaruso C, Giordanetti S, De Amici E. , et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110 (01) 22-26 17 Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25 (08) 1458-1463 18 Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171 (6 Pt 1): 2341-2345 19 Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994; 140 (10) 930-937 20 Saltzman EA, Guay AT, Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 2004; 172 (01) 255-258 21 Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19 (01) 95-98 22 Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. ; Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166 (02) 207-212 23 Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?. Urology 2000; 56 (02) 302-306 24 Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171 (20) 1797-1803 25 Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139 (03) 161-168 26 Pohjantähti-Maaroos H, Palomäki A, Hartikainen J. Erectile dysfunction, physical activity and metabolic syndrome: differences in markers of atherosclerosis. BMC Cardiovasc Disord 2011; 11: 36 27 Montorsi P, Ravagnani PM, Galli S. , et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006; 27 (22) 2632-2639 28 Miner MM. Erectile dysfunction and the “window of curability”: a harbinger of cardiovascular events. Mayo Clin Proc 2009; 84 (02) 102-104 29 Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294 (23) 2996-3002 30 Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998; 60 (04) 458-465 31 Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl. 01) 26-33 32 van Moorselaar RJA, Hartung R, Emberton M. , et al; ALF-ONE Study Group. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int 2005; 95 (04) 603-608 33 Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002; 324 (7345): 1059-1061 34 Gonzalez RR, Kaplan SA. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2006; 2 (04) 609-617 35 Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. J Sex Med 2009; 6 (08) 2299-2304 36 Rosen R, Altwein J, Boyle P. , et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (06) 637-649 37 Scranton RE, Goldstein I, Stecher VJ. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med 2013; 10 (02) 551-561 38 Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34 (04) 327-331 39 Nehra A, Jackson G, Miner M. , et al. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol 2013; 189 (06) 2031-2038 40 Böhm M, Baumhäkel M, Teo K. , et al; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121 (12) 1439-1446 41 Montorsi EC. 2006 Londoño (Miner Mayo Clinic Proc- 2009). Thompson: JAMA; 2005 42 Nehra A, Jackson G, Miner M. , et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87 (08) 766-778 43 DeBusk R, Drory Y, Goldstein I. , et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel. Am J Cardiol 2000; 86 (02) 175-181 44 Levine GN, Steinke EE, Bakaeen FG. , et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2012; 125 (08) 1058-1072 45 Wang C, Nieschlag E, Swerdloff R. , et al; International Society of Andrology (ISA); International Society for the Study of Aging Male (ISSAM); European Association of Urology (EAU); European Academy of Andrology (EAA); American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30 (01) 1-9 46 Wu FC, Tajar A, Beynon JM. , et al; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363 (02) 123-135 47 Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60 (07) 762-769 48 Vignozzi L, Morelli A, Filippi S. , et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007; 4 (03) 620-632 49 Morelli A, Filippi S, Mancina R. , et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145 (05) 2253-2263 50 Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7 (01) 46-56 51 Hamidi Madani A, Heidarzadeh A, Akbari Parsa N, Khosravi Darestani F, Hamidi Madani Z. A survey on relative frequency of metabolic syndrome and testosterone deficiency in men with erectile dysfunction. Int Urol Nephrol 2012; 44 (03) 667-672 52 Crawford ED, Barqawi AB, O'Donnell C, Morgentaler A. The association of time of day and serum testosterone concentration in a large screening population. BJU Int 2007; 100 (03) 509-513 53 Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58 (06) 710-717 54 Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. , The Laboratory Diagnosis of Testosterone Deficiency. White Paper. 2013 American Urological Association Education and Research, Inc. 55 Hellstrom WJ, Paduch D, Donatucci CF. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review. Int Urol Nephrol 2012; 44 (01) 61-70 56 de Ronde W, van der Schouw YT, Pols HAP. , et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem 2006; 52 (09) 1777-1784 57 Knoblovits P, Costanzo PR, Valzacchi GJ. , et al. Erectile dysfunction, obesity, insulin resistance, and their relationship with testosterone levels in eugonadal patients in an andrology clinic setting. J Androl 2010; 31 (03) 263-270 58 Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Maggi M. Testosterone and cardiovascular risk in patients with erectile dysfunction. J Endocrinol Invest 2012; 35 (09) 809-816 59 Testosterone Prescriptions Plunge After CVD. Signals, FDA Alert – Medscape. Marlene Busko; 2018 60 Lin JW, Lee JK, Wu CK. , et al. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011; 8 (08) 2350-2360 61 García-Cruz E, Leibar-Tamayo A, Romero J. , et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med 2013; 10 (10) 2529-2538 62 Laaksonen DE, Niskanen L, Punnonen K. , et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003; 149 (06) 601-608 63 Laaksonen DE, Niskanen L, Punnonen K. , et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90 (02) 712-719 64 Corona G, Monami M, Rastrelli G. , et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8 (01) 272-283 65 Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. Am J Med 2017; 130 (03) 293-305 66 Guay AT, Traish A. Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction. Urol Clin North Am 2011; 38 (02) 175-183 67 Nieschlag E, Swerdloff R, Behre HM. , et al; International Society of Andrology (ISA); International Society for the Study of the Aging Male (ISSAM); European Association of Urology (EAU). Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48 (01) 1-4 68 Bhasin S, Cunningham GR, Hayes FJ. , et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91 (06) 1995-2010 69 Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K. ; British Society for Sexual Medicine. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction. J Sex Med 2008; 5 (08) 1841-1865 70 Carani C, Isidori AM, Granata A. , et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90 (12) 6472-6479 71 Vigen R, O'Donnell CI, Barón AE. , et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310 (17) 1829-1836 72 Finkle WD, Greenland S, Ridgeway GK. , et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9 (01) e85805 Doi: 10.1371/journal.pone.0085805 73 http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf 74 Burnett AL, Nehra A, Breau RH. , et al. American Urological Association (AUA) ERECTILE DYSFUNCTION: AUA GUIDELINE. American Urological Association Education and Research, Inc; 2018 75 McDougal W, Wein A, Kavoussi L. , et al. Campbell-Walsh Urology. 10th Edition. SECTION XVI q Prostate. Chapter 93–94. Saunders: Philadelphia; 2012 76 Peltier A, van Velthoven R, Roumeguère T. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol 2009; 21 (04) 303-309 77 Hatzimouratidis K. (Chair), Giuliano F, Moncada I, Muneer A, Salonia A. (Vice-chair), Verze P. EUA Guidelines on Erectile Dysfunction, Premature Ejaculation, Penile Curvature and Priapism. European Association of Urology; 2016 78 J Endocrinology. Krasas Mayo 2008. J. Endocrology 2005- Carani Cesar Diciembre 2005 79 Sikka SC, Hellstrom WJ, Brock G, Morales AM. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J Sex Med 2013; 10 (01) 120-129 80 Trombetta C, Mazzon G, Liguori G. , et al. Clinical Evaluation of Erectile Dysfunction in the Era of PDE-5 Inhibitors: The Residual Role of Penile Color Doppler US (Chapter IV). In: Bertolotto M, Trombetta C. (editors). Scrotal Pathology (Medical Radiology/Diagnostic Imaging). Springer: Berlin; 2008: 22 81 Schwartz AN, Lowe M, Berger RE, Wang KY, Mack LA, Richardson ML. Assessment of normal and abnormal erectile function: color Doppler flow sonography versus conventional techniques. Radiology 1991; 180 (01) 105-109 82 Bertolotto M, Lissiani A, Pizzolato R, Fute MD. Common Findings and Anatomical Variations. (Chapter V). In: Bertolotto M, Trombetta C. (editors). Scrotal Pathology (Medical Radiology / Diagnostic Imaging). Springer: Berlin; 2008: 42-28 83 Broderick GA, Arger P. Duplex Doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol 1993; 28 (01) 43-56 84 Lee B, Sikka SC, Randrup ER. , et al. Standardization of penile blood flow parameters in normal men using intracavernous prostaglandin E1 and visual sexual stimulation. J Urol 1993; 149 (01) 49-52 85 Montorsi F, Sarteschi M, Maga T. , et al. Functional anatomy of cavernous helicine arterioles in potent subjects. J Urol 1998; 159 (03) 808-810 86 Bertolotto M, Neumaier CE, Martinoli C, Quaia E, Savoca G. Color Doppler appearance of penile cavernosal-spongiosal communications in patients with normal and impaired erection. Eur Radiol 2002; 12 (09) 2287-2293 87 Mancini M, Bartolini M, Maggi M, Innocenti P, Villari N, Forti G. Duplex ultrasound evaluation of cavernosal peak systolic velocity and waveform acceleration in the penile flaccid state: clinical significance in the assessment of the arterial supply in patients with erectile dysfunction. Int J Androl 2000; 23 (04) 199-204 88 Aversa A, Sarteschi LM. The role of penile color-duplex ultrasound for the evaluation of erectile dysfunction. J Sex Med 2007; 4 (05) 1437-1447 89 Valji K, Bookstein JJ. Diagnosis of arteriogenic impotence: efficacy of duplex sonography as a screening tool. AJR Am J Roentgenol 1993; 160 (01) 65-69 90 Ga B. Color dúplex Doppler ultrasound: penile blood flow study.Male infertility and sexual dysfunction Ed. WJG Hellstrom New York: Inc; 1997: 367-395 91 Golijanin D, Singer E, Davis R, Bhatt S, Seftel A, Dogra V. Doppler evaluation of erectile dysfunction - part 1. Int J Impot Res 2007; 19 (01) 37-42 92 Golijanin D, Singer E, Davis R, Bhatt S, Seftel A, Dogra V. Doppler evaluation of erectile dysfunction - part 2. Int J Impot Res 2007; 19 (01) 43-48 93 Halls J, Bydawell G, Patel U. Erectile dysfunction: the role of penile Doppler ultrasound in diagnosis. Abdom Imaging 2009; 34 (06) 712-725 94 Kim ED, Blackburn D, McVary KT. Post-radical prostatectomy penile blood flow: assessment with color flow Doppler ultrasound. J Urol 1994; 152 (6 Pt 2): 2276-2279 95 Wespes E, Raviv G, Vanegas JP. , et al. Corporeal veno-occlusive dysfunction: a distal arterial pathology?. J Urol 1998; 160 (6 Pt 1): 2054-2057 96 de Meyer JM, Thibo P. The correlation among cavernous pressure, penile rigidity and resistance index. J Urol 1998; 160 (01) 63-66 97 Sanda MG, Dunn RL, Michalski J. , et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358 (12) 1250-1261 98 Ficarra V, Novara G, Ahlering TE. , et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 62 (03) 418-430 99 Moskovic DJ, Miles BJ, Lipshultz LI, Khera M. Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. Int J Impot Res 2011; 23 (05) 181-192 100 Hyun JS. Prostate cancer and sexual function. World J Mens Health 2012; 30 (02) 99-107 101 Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008; 18 (06) 613-620 102 Salonia A, Burnett AL, Graefen M. , et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol 2012; 62 (02) 261-272 103 Wespes E, Eardley I, Giuliano F. , et al. Male sexual Dysfunction: Erectile dysfunction and premature ejaculation. EAU. Update 2013 104 Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med 2013; 10 (Suppl. 01) 102-111 105 Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol Clin North Am 2001; 28 (02) 309-319 106 Isidori AM, Giannetta E, Gianfrilli D. , et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63 (04) 381-394 107 Kostis JB, Jackson G, Rosen R. , et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 2005; 96 (02) 313-321 108 Althof SE, Rosen R, Rubio-Aurioles E. , et al. Psychologic and interpersonal aspects and their management. In: Porst H, Buvat J. (eds). Standard Practice in Sexual Medicine. Malden: Blackwell Publishing; 2006: 18-30 109 Yuan J, Zhang R, Yang Z. , et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63 (05) 902-912 110 Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002; 53 (Suppl. 01) 61S-65S 111 Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (2, Suppl): 12-27 112 Hellstrom WJ, Gittelman M, Karlin G. , et al; Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61 (04) (Suppl. 01) 8-14 113 Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int J Impot Res 2004; 16 (06) 470-478 (level I) 114 Stief C, Porst H, Sáenz De Tejada I, Ulbrich E, Beneke M. ; Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58 (03) 230-239 115 Interaction with Alcohol. Levitra interview form. 7th ed. 2007 116 Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 01) S57-S64 117 Brock GB, McMahon CG, Chen KK. , et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Pt 1): 1332-1336 118 Kloner RA, Jackson G, Hutter AM. , et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97 (12) 1778-1784 119 Chen Y, Cui S, Lin H. , et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 2012; 24 (06) 217-220 120 Safety Interaction with Alcohol. Ciallis interview form. 2007 121 Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170 (6 Pt 1): 2356-2358 122 Barada J. Salvage of ‘sildenafil (Viagra) failures’ benefits of patient and retreatment with sildenafil. Int J Impot Res 2001; 13 (Suppl. 04) S49-S50 123 Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int J Impot Res 2006; 18 (02) 146-149 124 Wang R, Burnett AL, Heller WH. , et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. J Sex Med 2012; 9 (08) 2122-2129 125 Kyle JA, Brown DA, Hill JK. Avanafil for erectile dysfunction. Ann Pharmacother 2013; 47 (10) 1312-1320 126 Wang H, Yuan J, Hu X, Tao K, Liu J, Hu D. The effectiveness and safety of avanafil for erectile dysfunction: a systematic review and meta-analysis. Curr Med Res Opin 2014; 30 (08) 1565-1571 127 Goldstein I, McCullough AR, Jones LA. , et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med 2012; 9 (04) 1122-1133 128 Sur RL, Kane CJ. ; RL. Sildenafil citrate-associated priapism. Urology 2000; 55 (06) 950 129 King SH, Hallock M, Strote J, Wessells H. Tadalafil-associated priapism. Urology 2005; 66 (02) 432 130 Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994; 14 (01) 38-44 131 McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2 (03) 415-425 , discussion 425–427 132 Porst H, Giuliano F, Glina S. , et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50 (02) 351-359 133 Rajfer J, Aliotta PJ, Steidle CP, Fitch III WP, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007; 19 (01) 95-103 134 Zumbé J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol 2008; 54 (01) 204-210 135 Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47 (02) 214-220 , discussion 220–222 136 Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19 (02) 200-207 137 Aversa A, Vitale C, Volterrani M. , et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008; 25 (01) 37-44 138 Porst H, Gacci M, Büttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol 2014; 65 (02) 455-464 139 Linet OI, Ogrinc FG. ; The Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334 (14) 873-877 140 Padma-Nathan H, Hellstrom WJ, Kaiser FE. , et al; Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336 (01) 1-7 141 Garrido Abad P, Sinués Ojas B, Martínez Blázquez L, Conde Caturla P, Fernández Arjona M. Safety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitors. Actas Urol Esp 2015; 39 (10) 635-640 142 Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15 (01) 78-82 143 Sun L, Peng FL, Yu ZL, Liu CL, Chen J. Combined sildenafil with vacuum erection device therapy in the management of diabetic men with erectile dysfunction after failure of first-line sildenafil monotherapy. Int J Urol 2014; 21 (12) 1263-1267 144 Engel JD. Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol 2011; 18 (03) 5721-5725 145 Nason GJ, McNamara F, Twyford M. , et al. Efficacy of vacuum erectile devices (VEDs) after radical prostatectomy: the initial Irish experience of a dedicated VED clinic. Int J Impot Res 2016; 28 (06) 205-208 146 Mulhall JP, Bivalacqua TJ, Becher EF. Standard operating procedure for the preservation of erectile function outcomes after radical prostatectomy. J Sex Med 2013; 10 (01) 195-203 147 Alemozaffar M, Regan MM, Cooperberg MR. , et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306 (11) 1205-1214 148 Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA 2005; 293 (21) 2648-2653 149 Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. J Sex Med 2009; 6 (09) 2538-2546 150 Walsh PC. The discovery of the cavernous nerves and development of nerve sparing radical retropubic prostatectomy. J Urol 2007; 177 (05) 1632-1635 151 Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 2009; 6 (08) 415-427 152 Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT. Factors predicting recovery of erections after radical prostatectomy. J Urol 2000; 164 (06) 1929-1934 153 Tal R, Teloken P, Mulhall JP. Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members. J Sex Med 2011; 8 (08) 2370-2376 154 Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55 (02) 334-347 155 Padma-Nathan H, McCullough A, Giuliano F. , et al. Postoperative nightly administration of sildenafil citrate significantly improved the return of normal spontaneous erectile function after bilateral nerve-sparing radical pros- tatectomy. J Urol 2003; 4: 375 156 Mulhall J, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2 (04) 532-540 , discussion 540–542 157 Gallo L, Perdonã S, Autorino R. , et al. Recovery of erection after pelvic urologic surgery: our experience. Int J Impot Res 2005; 17 (06) 484-493 158 Brock G, Nehra A, Lipshultz LI. , et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170 (4 Pt 1): 1278-1283 159 Montorsi F, Brock G, Lee J. , et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54 (04) 924-931 160 Kovanecz I, Rambhatla A, Ferrini MG. , et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008; 101 (02) 203-210 161 Vignozzi L, Filippi S, Morelli A. , et al. Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med 2006; 3 (03) 419-431 162 Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol 2006; 16 (03) 186-195 163 Montorsi F, Guazzoni G, Strambi LF. , et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158 (04) 1408-1410 164 Raina R, Agarwal A, Ausmundson S. , et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18 (01) 77-81 165 Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2013; 111 (04) 658-665 166 Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharma- cological penile rehabilitation: Practice patterns among ISSM practitioners. J Sex Med 2009; 6: 2032-2038 167 Dall'era JE, Mills JN, Koul HK, Meacham RB. Penile rehabilitation after radical prostatectomy: important therapy or wishful thinking?. Rev Urol 2006; 8 (04) 209-215 168 Salonia A, Burnett AL, Graefen M. , et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012; 62 (02) 273-286 169 Babaei AR, Safarinejad MR, Kolahi AA. Penile revascularization for erectile dysfunction: a systematic review and meta-analysis of effectiveness and complications. Urol J 2009; 6 (01) 1-7 170 Henry GD, Brinkman MJ, Mead SF. , et al. A survey of patients with inflatable penile prostheses: assessment of timing and frequency of intercourse and analysis of implant durability. J Sex Med 2012; 9 (06) 1715-1721 171 Scherzer ND, Dick B, Gabrielson AT, Alzweri LM, Hellstrom WJG. Penile Prosthesis Complications: Planning, Prevention, and Decision Making. Sex Med Rev 2018 172 Bettocchi C, Palumbo F, Spilotros M. , et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010; 7 (1 Pt 1): 304-309 173 Carvalheira A, Santana R, Pereira NM. Why are men satisfied or dissatisfied with penile implants? A mixed method study on satisfaction with penile prosthesis implantation. J Sex Med 2015; 12 (12) 2474-2480 174 Montague DK, Angermeier KW. Penile prosthesis implantation. Urol Clin North Am 2001; 28 (02) 355-361 , x 175 Wang R, Howard GE, Hoang A, Yuan JH, Lin HC, Dai YT. Prospective and long-term evaluation of erect penile length obtained with inflatable penile prosthesis to that induced by intracavernosal injection. Asian J Androl 2009; 11 (04) 411-415 176 Levine LA, Becher EF, Bella AJ. , et al. Penile Prosthesis Surgery: Current Recommendations From the International Consultation on Sexual Medicine. J Sex Med 2016; 13 (04) 489-518 177 Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J 2017; 93 (1105): 679-685 178 Khera M, Albersen M, Mulhall JP. Mesenchymal stem cell therapy for the treatment of erectile dysfunction. J Sex Med 2015; 12 (05) 1105-1106 179 Frey A, Sønksen J, Fode M. Low-intensity extracorporeal shockwave therapy in the treatment of postprostatectomy erectile dysfunction: a pilot study. Scand J Urol 2016; 50 (02) 123-127 180 Gruenwald I, Appel B, Kitrey ND, Vardi Y. Shockwave treatment of erectile dysfunction. Ther Adv Urol 2013; 5 (02) 95-99 181 Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 2012; 9 (01) 259-264 182 Sexual Medicine Society. POSITION STATEMENT: ED Restorative (Regenerative) Therapies (shock waves, autologous platelet rich plasma, and stem cells). Available at: http://email.mg.smsna.org/c/eJwNjsFuhCAURb9Gl0SQUViwmEW7a9OMTbfkIU8kHcXwsGb-viQ3N-euzvXGOwm8jWYZe6dUp2_D7PueK-GFGpXUXmktsXON7EJiVKCcdDxPYjuWdjWoRtTzwgWgk7cFB1CAcuBSDJ0ehWifZi3laPp7I95rrutitNEOLOVQ9w-vFTcISBWmj-nzbr8SxRLTbqdqww33Yh9v9oFUUoYS_9B-r5jhiEjs8EubjcvJY47zLwsZQ8qv-naDV2Loz38FZUqA 183 Hackett G, Kirby M, Wylie K. , et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in Men—2017. J Sex Med 2018; 15 (04) 430-457 184 Thirumavalavan N, Hoover CRV, Gross MS. Surgeons Corner: Cavernoscopy for Rear Tip Extender Removal. J Sex Med 2018; 15 (08) 1195-1197 185 Kim BH, Lim HS, Chung JY. , et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008; 65 (06) 848-854 186 Glina S, Toscano I, Gomatzky C. , et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009; 6 (02) 553-557 187 Moon KH, Ko YH, Kim SW. , et al. Efficacy of once-daily administration of udenafil for 24 weeks on erectile dysfunction: results from a randomized multicenter placebo-controlled clinical trial. J Sex Med 2015; 12 (05) 1194-1201 188 Hatzimouratidis K, Salonia A, Adaikan G. , et al. Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2016; 13 (04) 465-488
